Form D · Other
Small Pharma Ltd.
London, X0 · CIK 0001847727
Offering snapshot reported Feb 24, 2021 · SEC filing
- Reported sold
- $1.86M Offering amount: $1.86M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 25, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 24, 2021 | Initial | $1,864,613 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-390363
U.S. dollar amounts are based on the Bank of Canada exchange rate 0.7851 reported on January 25, 2021.
Convertible loan notes bearing 6% interest per annum maturing on July 1, 2021. Each note is convertible into shares of the Issuer prior to the occurrence of certain events.
Source: Form D, filed Feb 24, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Khalid Howladar | Director |
| Marie Claire Layzell | Director, Executive |
| Peter Rands | Director, Executive |
| Carol Routledge | Executive |
| George Tziras | Director |
Issuer details
Industry: Other (See others in industry)
Address:
3 Rd Floor, 6 8 Bonhill Street
London, X0, EC2A 4BX
London, X0, EC2A 4BX